PCM
AUPH icon

Pinz Capital Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Pinz Capital Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-136,200
Closed -$2.76M – 140
2019
Q4 		$2.76M Buy
+136,200
New +$1.25M 1.01% 22

Other funds holding AUPH

HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Pinz Capital Management's AUPH Position: Q1 2020 in Review

Pinz Capital Management sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2020, closing a stake of 136,200 shares — an estimated $2.76M sold.

Pinz Capital Management first reported a position in AUPH in Q4 2019 and held it in 1 quarter. The position peaked at $2.76M in Q4 2019. 125 funds tracked by Wall St. Rank hold AUPH as of Q1 2020.

  • Pinz Capital Management reported no remaining Aurinia Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Pinz Capital Management sold 136,200 Aurinia Pharmaceuticals shares in Q1 2020, an estimated $2.76M.
  • Pinz Capital Management first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Pinz Capital Management's Aurinia Pharmaceuticals position peaked at $2.76M in Q4 2019.
  • 125 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2020.

Based on Pinz Capital Management's 13F filing for Q1 2020, filed 12 May 2020.